Dr. Wolchok on Progress After Anti-PD-1 Monotherapy in Melanoma

Video

In Partnership With:

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, 2014 Giant of Cancer Care in Melanoma, discusses an ongoing clinical trial that will explore optimal treatments for patients with melanoma who fail on a PD-1 inhibitor as a single agent.

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, 2014 Giant of Cancer Care in Melanoma, discusses an ongoing clinical trial that will explore optimal treatments for patients with melanoma who fail on a PD-1 inhibitor as a single agent.

How to treat patients who relapse on PD-1 monotherapy is a challenging question, Wolchok explains. Therefore, a clinical trial will randomize patients with metastatic melanoma who have progressed on this treatment to ipilimumab (Yervoy) or ipilimumab plus nivolumab (Opdivo; NCT02731729). There is a vast difference in the toxicity profile between both options, Wolchok explains.

The dosing regimens to be studied will be 3 mg/kg of ipilimumab and 1 mg/kg of nivolumab, which is the dosing schedule used in the CheckMate-067 trial, and a flipped dose of 3 mg/kg of nivolumab and 1 mg/kg of ipilimumab to try to improve the safety to efficacy profile. This is a regimen that has been explored in renal cell carcinoma, urothelial cancer, and non—small cell lung cancer.

Wolchok says he is still very comfortable with administering the combination of 3 mg/kg of iplilimumab and 1 mg/kg of nivolumab to patients until further research demonstrates different findings.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,